Clinical Trial

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2025-04-16; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2025-05-16
Trial Details
NCT Number NCT06934044
Lead Sponsor Hoffmann-La Roche
Conditions Multiple Myeloma
Enrollment 20 participants
Start Date 2025-05-13
Primary Completion 2028-11-15 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-06